When it finally brings its GenESA System to the U.S. market in the third quarter, Gensia Sicor still will not be selling the coronary artery disease diagnostic system for the full indication the company had sought. But having waited and worked as long as it has - GNSA has been through two rounds of alterations to its NDA since early 1995 -the company said it is determined to go after the remainder of the indication as soon as possible (see BioCentury Extras, April 11, 1995, and April 30, 1996).

Whether this contested slice of the coronary artery disease (CAD) market is worth all the fuss, however, may be in the